Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT07876531
Starting soon Phase 1

A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity

NCT07876531 · tracked via the Priya Life Science USA tracker
Sponsor
Pfizer
Phase
Phase 1
Started
2026-10-16
Last updated
2026-10-15

Condition(s) studied

Overweight and/or ObesityHealthy Participants

Investigational drug(s) / intervention(s)

Berobenatide →

Berobenatide: Solution for Injection

Study summary

This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.

The study involves multiple clinic visits at a study site over the length of the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Key Inclusion Criteria: * Participants 18 years of age or older * BMI of 27-45 kg/m2; and a total body weight \>50 kg (110 lb) Key Exclusion Criteria: * Pregnant or breastfeeding women, or those planning pregnancy during the study * History of other chronic disorders * Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC * Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect gastrointestinal (GI) motility * Acute GI symptoms at screening, Day -1, or prior to administration of study intervention

Primary outcome measure(s)

  • Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Berobenatide — Up to 85 days
  • PK: Maximum Observed Concentration (Cmax) of Berobenatide — Up to 85 days

Trial sites (1)

FacilityCityRegionStatus
Anaheim Clinical Trials, LLC Anaheim California

More Pfizer trials in the USA

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] Recruiting
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Active, not recruiting
A Study to Learn About the Safety of PENBRAYA During Pregnancy Recruiting
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Starting soon

Other trials for the same condition

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Starting soon
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants Recruiting
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women Recruiting
Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07876531 on ClinicalTrials.gov ↗ ← All trials in the USA